CDSCO Panel Approves Eli Lilly's protocol amendment proposal for Adjuvant Imlunestrant vs Standard Adjuvant study

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Eli Lilly's protocol amendment proposal for Adjuvant Imlunestrant vs Standard Adjuvant study.

This came after Eli Lilly presented protocol amendment (d) dated 05 Feb 2024 and India ICF V7.0 dated 21 Feb 2024 protocol No. J2J-MC-JZLH.

Imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.

Imlunestrant features pure antagonistic properties that cause continuous inhibition of ER-dependent gene transcription and cell growth.

At the recent SEC meeting for Oncology held on the 3rd and 4th of April 2024, the expert panel reviewed the proposal for the protocol amendment of the Adjuvant Imlunestrant vs Standard Adjuvant study presented by the drug major Eli Lilly.

After detailed deliberation, the committee recommended the approval of protocol amendment as presented by the firm.

Also Read: Conduct Phase III clinical trial: CDSCO Panel Tells BDR Pharmaceutical on Anti-cancer Drug Abiraterone Acetate